---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product comparison"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Product comparison. Topics: Cross-trial context for AD109 and tirzepatide in an editorial on SynAIRgy; Comparator: tirzepatide in moderate-to-severe OSA with obesity, AHI with 4% desaturation hypopnea rule; Review comparison of OSA pharmacotherapies, SynAIRgy figures under the treatment policy estimand; Investigational comparator: sulthiame in the FLOW phase 2 trial, AHI with 3% desaturation or arousal hypopnea rule; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Head-to-head and indirect comparisons of AD109 with other OSA treatments

No evidence found.

<a id="topic-2.1.2.14-2"></a>

### Cross-trial context for AD109 and tirzepatide in an editorial on SynAIRgy

> “In the SURMOUNT-OSA trials, tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist, produced substantially larger reductions in AHI than AD109, although direct comparisons are limited by important differences in study populations, including markedly higher baseline AHI and body mass index in SURMOUNT-OSA and greater potential for placebo effect.”
> “Whereas tirzepatide primarily targets metabolic contributors to airway collapse through weight reduction and is therefore most applicable to patients with obesity, AD109 targets upper airway neuromuscular dysfunction and may have applicability across a broader spectrum of patients with OSA.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.1.2.14-3"></a>

### Comparator: tirzepatide in moderate-to-severe OSA with obesity, AHI with 4% desaturation hypopnea rule

> “which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%”
> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.1.2.14-4"></a>

### Review comparison of OSA pharmacotherapies, SynAIRgy figures under the treatment policy estimand

> “Although AD109 demonstrated statistically significant therapeutic efficacy compared with placebo, the reductions in the AHI and oxygen desaturation index were only 3.3/h and 3.7/h, respectively.”
> “These findings suggest that long-term tolerability and safety may remain challenging [28].”
> “Although tirzepatide is currently the only U.S. Food and Drug Administration-approved medication for OSA, it is expected that OSA-directed pharmacotherapy unrelated to weight loss that is effective for patients who refuse or discontinue PAP therapy may become available in the near future.”

Source: [Kim (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434379/)

<a id="topic-2.1.2.14-5"></a>

### Investigational comparator: sulthiame in the FLOW phase 2 trial, AHI with 3% desaturation or arousal hypopnea rule

> “Adults (aged 18–75 years) with untreated, moderate to severe OSA and an Apnoea–Hypopnea Index (AHI) of ≥15 to ≤50 events per h were randomly assigned (1:1:1:1), using interactive response technology, to receive placebo or sultiame 100 mg, 200 mg, or 300 mg tablets of identical appearance once per day at bedtime for 15 weeks.”
> “In the full analysis set, placebo-subtracted relative AHI3a adjusted means change at week 15 was –16·4% (95% CI –31·3 to –1·4; p=0·032), –30·2% (–45·4 to –15·1; p<0·0001), and 34·6% (–49·1 to –20·0; p<0·0001) for sultiame 100 mg, 200 mg, and 300 mg, respectively.”
> “Events reported in more than 10% of patients in the placebo, 100 mg, 200 mg, or 300 mg groups were paraesthesia (seven [9%] of 75, 16 [22%] of 74, 32 [43%] of 74, 43 [57%] of 75), headache (six [8%], five [7%], 12 [16%], 11 [15%]), COVID-19 (three [4%], three [4%], six [8%], ten [13%]), and nasopharyngitis (nine [12%], three [4%], seven [9%], seven [9%]).”

Source: [Randerath et al. (2025)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01196-1/fulltext)

<a id="topic-2.1.2.14-6"></a>

### Sulthiame rights transferred from Apnimed to Shionogi

> “In April 2026, we completed the SASS Disposition pursuant to the MIPA and concurrently all of our rights and obligations under the Desitin APA were transferred to Shionogi.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.14-7"></a>

### Investigational comparator: IHL-42X (dronabinol and acetazolamide) in the RePOSA phase 2 portion

> “The study enrolled 121 subjects across 16 clinical trial sites in the United States and was conducted in accordance with an IND cleared by the FDA.”
> “The low-dose and high-dose IHL-42X groups achieved a statistically significant reduction in percent change in AHI from baseline compared to placebo (p<0.05), the primary measure of OSA severity.”
> “Notably, 33.3% of patients in the low-dose group and 41.2% in the high-dose group achieved a greater than 30% reduction in AHI, while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%, demonstrating a strong therapeutic response in a substantial subset of the population.”
> “The DReAMzz Study commenced in May 2026, with screening beginning in July 2026. The next major milestone is completion of the DReAMzz Study, estimated for mid-2027, followed by analysis to inform dose selection and the planned Phase 3 design.”
> “Competitors in the OSA drug development space include Apnimed, Inc. and Mineralys Therapeutics.”

Source: [Incannex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/ixhl-20260630.htm)

<a id="topic-2.1.2.14-8"></a>

### Hypoglossal nerve stimulation manufacturer statement on AD109 as a competing product

> “The product is in phase 3 clinical development.”
> “In Europe, the Genio system is CE-Mark certified for use as a second-line therapy in the treatment of moderate to severe OSA in patients who do not tolerate, refused or failed positive airway pressure, or PAP, therapy.”

Source: [Nyxoah Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1857190/000110465926035161/nyxh-20251231x20f.htm)

<a id="topic-2.1.2.14-9"></a>

### Manufacturer description of competing treatments

> “We will additionally face competition from surgically implanted devices, such as Inspire® by Inspire, a hypoglossal nerve stimulation system that is targeted to a subset of OSA patients.”
> “There are also several programs in clinical and preclinical development to treat OSA by pharmaceutical companies including Kyorin Pharmaceutical Co., Ltd., Incannex Healthcare Ltd. and Mosanna Therapeutics.”
> “Tirzepatide targets the weight-related anatomical cause of OSA. It does not address the underlying neuromuscular cause of OSA. This therapy is relevant for less than approximately 20% of the total OSA population, as it is not indicated for patients without obesity or for those with mild OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

Additional sources: [Hedner et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35202553/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
